On The Radar – 18th Edition
By
Pharma R&D investment dipped as companies shift from volume to precision, prioritizing high-value therapeutic areas like oncology and metabolic disease. Rather than broad discovery, firms are doubling down on targeted innovation and strategic acquisitions.
➡ Why it matters: Fewer bets, bigger stakes. Future drug pipelines will be more concentrated and likely more expensive.
Patent protections and “evergreening” continue to shield drugs from competition, allowing manufacturers to maintain high prices long after initial development. Reform efforts are increasingly focused on breaking these monopolies.
➡ Why it matters: Without competition, pricing power remains unchecked and cost pressure persists downstream.
Employer-sponsored coverage remains the backbone of U.S. healthcare, but rising premiums and specialty drug costs are putting that model under strain. Sustainability is becoming a central concern.
➡ Why it matters: The system isn’t broken, but it is under pressure. Employers must evolve how they manage cost.
Employers are moving toward more active benefit strategies, leveraging data, AI, and personalized care models to improve outcomes while controlling costs. Passive plan design is quickly becoming outdated.
➡ Why it matters: Managing healthcare is no longer administrative. It is strategic.
Federal reforms, direct-to-consumer pricing benchmarks, and PBM delinking are reshaping how drugs are priced and purchased. Transparency is becoming embedded in the system.
➡ Why it matters: The pricing model itself is being rebuilt, not just adjusted.
Patent strategies, intermediary incentives, and lack of negotiation power continue to define the U.S. drug pricing problem. Transparency alone is not enough without structural change.
➡Why it matters: Cost drivers are interconnected. Solving one piece without the others will fall short.
New reporting requirements and fiduciary expectations are pushing employers to take a more active role in managing pharmacy benefits. Passive oversight is no longer defensible.
➡Why it matters: With more visibility comes more responsibility and more risk.
Healthcare spending is approaching one-fifth of the U.S. economy, driven largely by specialty drugs and rising utilization. The financial impact is expanding beyond healthcare into the broader economy.
➡Why it matters: This is no longer just a healthcare issue. It is an economic one.
New legislation is forcing a shift to flat-fee PBM models with full rebate pass-through and greater pricing visibility. The traditional “black box” is being dismantled.
➡ Why it matters: Incentives across the supply chain are being realigned in real time.
Double-digit premium increases are pushing small businesses toward alternative funding strategies like level-funded plans and HRAs. Cost control is becoming a necessity, not a choice.
➡ Why it matters: Smaller employers are accelerating adoption of flexible, self-funded approaches.
The Consolidated Appropriations Act of 2026 is moving from legislation to implementation, requiring contract restructuring, new reporting, and active fiduciary oversight.
➡ Why it matters: Compliance is just the starting point. Execution will define outcomes.
Despite reform efforts, public concern over prescription drug costs continues to rise. Many patients have yet to feel the impact of policy changes at the pharmacy counter.
➡ Why it matters: Perception matters. If costs don’t come down in real terms, pressure will continue to build.
Rising premiums, GLP-1 demand, expiring subsidies, and new regulatory frameworks are converging to reshape the cost landscape. Employers are being forced to make difficult trade-offs.
➡ Why it matters: Cost pressure is coming from multiple directions at once.
Final Thoughts
Pharmacy and healthcare costs are no longer rising quietly in the background. They are being exposed, regulated, and restructured all at once. Employers who take an active, informed approach to managing these changes will be best positioned to navigate what comes next.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.